(Reported figures are for the full reporting period unless otherwise stated. Figures for the comparable reporting period last year is stated in parenthesis after realized figures.) Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced results for the first nine months of 2009. Exiqon expects full year revenue around DKK 130 million. Net loss is expected around DKK 130 million. • Revenue increased 3% to DKK 99.1 million (DKK 95.8 million). In the third quarter of 2009, revenue decreased 21% to DKK 40.6 million (DKK 51.3 million) due to one-time license revenue and associated reagent sales in the comparable period of 2008. • Operating expenses increased 16% to DKK 146.1 million (DKK 125.8 million). In the third quarter of 2009, operating expenses increased 13% to DKK 48.8 million (DKK 43.1 million) due to SG&A costs related to the diagnostics segment. • Net loss was DKK 108.3 million (DKK 73.6 million). In the third quarter of 2009, net loss was DKK 27.2 million (DKK 10.1 million). EPS amounted to DKK -3.58 (DKK -2.55) and DKK -0.90 (DKK -0.35) in the third quarter of 2009. • On 2 July 2009, Exiqon Diagnostics announced two new marketing initiatives: the launch of the ArQive™ Registry for clinical data collection, and the launch of the new PortiQo™ Doctor Portal web based customer communication tool. • In August, Exiqon Life Sciences was restructured and the cost base reduced by approximately DDK 40 million on a full year basis to ensure a positive cash flow from 2010. • On 15 September 2009, Exiqon Life Sciences announced the successful completion of several key milestones in a project for Tacere Therapeutics designing custom-designed RNAi for Pfizer, Inc. for commercialization of a potential single-administration treatment for Hepatitis C (HCV). • After end period, on 15 October 2009, Exiqon Life Sciences launched its new platform for quantitative real-time PCR analysis of microRNAs that combines all the advantages of Exiqon's proprietary LNA™ detection technology with a universal reverse transcription (RT) step, resulting in the most sensitive microRNA expression profiling system available today. • After end period, on 9 November 2009, Exiqon announced the appointment of Mark Willig as Chief Commercial Officer who is joining Exiqon from a position as Vice President of Global Sales for Thermo Fisher Scientific, Inc. CEO Lars Kongsbak says: “We are very excited about the recent launch of Exiqon's new platform for quantitative real-time PCR analysis of miRNAs and the potential it holds for miRNA biomarker profiling in all sample formats not least serum and FFPE samples. This important product launch follows a successful reorganization of Exiqon Life Sciences. We are optimistic that this product will allow Exiqon Life Sciences to cement its position as a leading supplier of research products for miRNA profiling.” See the full announcement at www.exiqon.com/investor/portal or in the attached PDF.
Exiqon A/S Interim report for the period 1 January - 30 September 2009 (unaudited)
| Quelle: Exiqon A/S